by Truveta staff | Jan 26, 2024 | Research
Truveta Research explored the rates of pediatric RSV immunizations and pediatric RSV-associated hospitalizations for children under the age of two. Of the 1,872,292 children under age two who were eligible to receive an RSV immunization, 3.7% of the eligible...
by Truveta staff | Sep 28, 2023 | Technology
It’s only September, but COVID-19 and respiratory syncytial virus (RSV) cases are already rising. The latest Truveta Research monitoring report shows that for people over 65, COVID continues to be the most prevalent respiratory virus associated with hospitalizations....
